L&G Healthcare Technology & Innovation UCITS ETF

ETF (UCITS compliant)
L&G Healthcare Technology & Innovation UCITS ETF
USD Accumulating ETF Class
ISINIE00BK5BC677
TER0.49%
ISINIE00BK5BC677
TER0.49%
Fund aim
The L&G Healthcare Technology & Innovation UCITS ETF (the "ETF") aims to track the performance of the ROBO Global® Healthcare Technology and Innovation Index TR (the “Index”).
Fund snapshot
- Long-term allocation
Long-term megatrend that we believe is radically transforming the way we live and work
- High growth potential
Aims to capture the outsized growth potential of the healthcare technology industry
- Leveraging industry expertise
An index tracking investment strategy that is supported by a team of healthcare technology experts
- Does it have a sustainable objective?
The Fund has a sustainable investment objective as it invests in companies which (i) contribute to social objectives, (ii) do not significantly harm any environmental or social objectives, and (iii) follow good governance practices. Further information can be found in the Fund Supplement.
Fund facts
| Fund size | |
| Base currency | USD |
| Fund launch date | 2 Jul 2019 |
| Share class launch | 2 Jul 2019 |
| Domicile | Ireland |
| Replication method | Physical - full replication |
Benchmark
ROBO Global® Healthcare Technology and Innovation Index TR
Index description
ROBO Global® Healthcare Technology and Innovation Index TR
The Index aims to track the performance of a basket of companies that are actively engaged in the healthcare technology value-chain.
The index is comprised of companies which are publicly traded on various stock exchanges around the world that have a distinct portion of their business and revenue derived from the field of healthcare technologies, and the potential to grow within this space through innovation and/or market adoption of their products and/or services. Companies are included in the index receive a "HTEC Score" comprised of factors representing (1)the levels of revenue the company receives from innovative healthcare technologies, (2) the levels of investment the firm makes in healthcare technologies, (3) the market and technology leadership of the firm within the universe.
A company is only eligible for inclusion in the Index if it is of a sufficient size (determined by reference to the total market value of its shares) and it is sufficiently "liquid" ( a measure of how actively its shares are traded on a daily basis). Within the Index, companies are weighted according a modified HTEC-factor weighting scheme. The Index is rebalanced quarterly in March, June, September and December.
Index data
| Provider | ROBO Global® |
| Bloomberg code | HTECTR |
| Reuters code | .HTECTR |
| Type | Total Return |
| Website | Go to website |
Performance
Performance scenarios
Example investment: 10,000 USD
Portfolio breakdown
As at 31 Oct 2026
| Top 10 constituents | 22.6% |
|---|---|
| Rest of Index | 77.4% |
| Number of constituents in Index | 61 |
|---|
Top 10 constituents (%)
| GRAIL | 2.8 |
| CareDx | 2.4 |
| Natera | 2.4 |
| Twist Bioscience | 2.3 |
| Intuitive Surgical | 2.2 |
| Moderna | 2.1 |
| Glaukos Corp. | 2.1 |
| Thermo Fisher Scientific | 2.1 |
| Guardant Health | 2.1 |
| Tempus AI | 2.0 |
Sector (%)
Health Care | 96.0 |
Consumer Staples | 2.5 |
Information Technology | 1.5 |
| Top 10 constituents | 22.6% |
|---|---|
| Rest of Index | 77.4% |
| Number of constituents in Index | 61 |
|---|
Top 10 constituents (%)
| GRAIL | 2.8 |
| CareDx | 2.4 |
| Natera | 2.4 |
| Twist Bioscience | 2.3 |
| Intuitive Surgical | 2.2 |
| Moderna | 2.1 |
| Glaukos Corp. | 2.1 |
| Thermo Fisher Scientific | 2.1 |
| Guardant Health | 2.1 |
| Tempus AI | 2.0 |
Sector (%)
Health Care | 96.0 |
Consumer Staples | 2.5 |
Information Technology | 1.5 |
Currency (%)
USD | 82.2 |
EUR | 6.9 |
CHF | 5.3 |
HKD | 3.3 |
JPY | 1.2 |
GBP | 1.1 |
Country (%)
United States | 76.3 |
Switzerland | 6.9 |
United Kingdom | 3.7 |
Netherlands | 3.4 |
Germany | 1.9 |
France | 1.8 |
China | 1.6 |
Italy | 1.3 |
Japan | 1.2 |
Other | 1.7 |
All data source LGIM unless otherwise stated. Totals may not sum to 100% due to rounding. The breakdowns shown relate to the Index. The ETF’s portfolio may deviate from the portfolio of the Index.
Fund managers

L&G Index Fund Management Team
The skill set and expertise we have developed over 35+ years in index management has allowed us to continuously evolve our investment processes. The Index Fund Management team comprises 30 fund managers with an average experience of 15 years, supported by 33 broader team members. Management oversight is provided by Dave Barron, Global Head of Index, ETFs & Systematic Solutions. The team also has full access to the resources and research of other specialists within L&G, including economists and strategists.
SFDR categorisation
Article 9
The sustainable investment objective of the Fund is to provide exposure to the global healthcare technology industry. The Fund seeks to achieve its investment objective by tracking the performance of the ROBO Global® Healthcare Technology and Innovation Index TR (the “Index”). The Index is a reference benchmark that has been designated for the purpose of attaining the sustainable investment objective of the Fund.
The sustainable investment objective of the Fund is to provide exposure to the global healthcare technology industry. The Fund seeks to achieve its investment objective by tracking the performance of the ROBO Global® Healthcare Technology and Innovation Index TR (the “Index”). The Index is a reference benchmark that has been designated for the purpose of attaining the sustainable investment objective of the Fund.
The Fund follows the following sustainability-related investment strategy by tracking the Index that applies:
Literature
Document type
Prices
Pricing information
| Price time | 16:00 EST (NY) |
| Currency | USD |
Listings and codes
Listings
| Exchange | Currency | Ticker | ISIN | Bloomberg | WKN | Reuters | Listing date | Trading hours (local) |
|---|---|---|---|---|---|---|---|---|
| SIX Swiss Exchange | CHF | DOCT | IE00BK5BC677 | DOCT SW | A2PM51 | DOCT.S | 05/06/2020 | 09:00 - 17:30 |
| London Stock Exchange | GBP | DOCG | IE00BK5BC677 | DOCG LN | A2PM51 | DOCG.L | 02/07/2019 | 08:00 - 16:30 |
| London Stock Exchange | USD | DOCT | IE00BK5BC677 | DOCT LN | A2PM51 | DOCT.L | 02/07/2019 | 08:00 - 16:30 |
| Borsa Italiana | EUR | DOCT | IE00BK5BC677 | DOCT IM | A2PM51 | LGDOCT.MI | 10/09/2019 | 09:00 - 17:30 |
| Deutsche Börse Xetra | EUR | XMLH | IE00BK5BC677 | XMLH GY | A2PM51 | DOCT.DE | 10/09/2019 | 09:00 - 17:30 |
Share class codes
| ISIN | IE00BK5BC677 |
| SEDOL | BKF3JJ5 |
| Bloomberg | DOCT |
| WKN | A2PM51 |
| Benchmark Bloomberg | HTECTR |
Dealing information
| Issuer | Legal & General UCITS ETF Plc |
| Depositary and Trustee | The Bank of New York Mellon SA/NV, Dublin Branch |
| Securities regulator | Central Bank of Ireland |
Country registration
This share class is registered for sale in the following countries:
* The Fund is on the list of restricted collective investment schemes, but is not authorised or recognised by the Monetary Authority of Singapore (the “MAS”) and the Shares cannot be offered or marketed to retail clients.




















